This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Mayank Patel: Innovator in Biopharmaceutical Compositions
Introduction
Mayank Patel is a notable inventor based in New City, NY (US). He has made significant contributions to the field of biopharmaceuticals, particularly in the area of reducing particle formation in drug products. His innovative work has the potential to enhance the efficacy and safety of biopharmaceutical compositions.
Latest Patents
Mayank Patel holds 1 patent for his invention titled "Methods of reducing particle formation and compositions formed thereby." This patent describes biopharmaceutical compositions and drug products that exhibit reduced amounts of subvisible particle formation. The compositions include a protein and a surfactant or stabilizer, featuring high percentage amounts (e.g., at least 97%) of a long-chain fatty acid ester. Additionally, the patent outlines methods for preparing and storing these compositions and drug products.
Career Highlights
Mayank Patel is currently employed at Regeneron Pharmaceuticals, Inc., where he applies his expertise in biopharmaceutical development. His work at Regeneron has positioned him as a key player in advancing innovative drug formulations that address critical healthcare needs.
Collaborations
Some of Mayank's coworkers include Stacy Wasinger and Danya Spritzer. Their collaborative efforts contribute to the dynamic research environment at Regeneron Pharmaceuticals, fostering innovation and excellence in biopharmaceutical development.
Conclusion
Mayank Patel's contributions to the field of biopharmaceuticals through his innovative patent demonstrate his commitment to improving drug formulations. His work not only enhances the understanding of particle formation but also paves the way for safer and more effective biopharmaceutical products.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
